Immune response in lung cancer patients on immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have non-small cell lung cancer (NSCLC) that is locally advanced or has spread to other parts of the body.
- You are about to start immunotherapy with a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab), with or without chemotherapy.
- You have never received immunotherapy before.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.